Published in Cancer Cell on August 14, 2012
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 3.21
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature (2016) 1.66
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma. Blood (2015) 1.39
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med (2014) 1.12
MYC and metabolism on the path to cancer. Semin Cell Dev Biol (2015) 1.09
B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol (2015) 1.08
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood (2014) 0.98
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol (2013) 0.94
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome. J Allergy Clin Immunol (2014) 0.92
The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol (2015) 0.91
Epo-induced erythroid maturation is dependent on Plcγ1 signaling. Cell Death Differ (2014) 0.90
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol (2015) 0.88
Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing. Leukemia (2013) 0.88
Burkitt lymphoma: much more than MYC. Cancer Cell (2012) 0.88
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. PLoS Pathog (2015) 0.86
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers (Basel) (2015) 0.86
Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol (2013) 0.86
The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis. Genes Dev (2015) 0.85
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res (2014) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination. J Immunol (2015) 0.83
Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009. APMIS (2013) 0.83
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol (2014) 0.83
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomark Res (2013) 0.81
Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget (2012) 0.81
Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model. Leukemia (2014) 0.80
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica (2014) 0.80
NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients. Oncotarget (2015) 0.79
New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization. Cancer Discov (2013) 0.79
MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. Infect Agent Cancer (2013) 0.79
GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. Blood (2016) 0.78
Massive transcriptional perturbation in subgroups of diffuse large B-cell lymphomas. PLoS One (2013) 0.77
The case of the missing c-Myc. Nat Immunol (2012) 0.77
Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas. Cell Commun Signal (2012) 0.77
Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained. Blood (2014) 0.77
New pathogenic mechanisms in Burkitt lymphoma. Nat Genet (2012) 0.77
Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation. Oncogene (2013) 0.76
KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice. PLoS Pathog (2015) 0.76
Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Targeted therapies: New targets in Burkitt lymphoma? Nat Rev Clin Oncol (2012) 0.75
Gsk3 is a metabolic checkpoint regulator in B cells. Nat Immunol (2017) 0.75
Mouse model for acute Epstein-Barr virus infection. Proc Natl Acad Sci U S A (2016) 0.75
Epigenetics, c-Myc and aggressive B-cell lymphomas. Oncotarget (2012) 0.75
The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes (Basel) (2017) 0.75
Role of MYC in B Cell Lymphomagenesis. Genes (Basel) (2017) 0.75
Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci (2016) 0.75
The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses. Immunity (2016) 0.75
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol (2017) 0.75
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget (2017) 0.75
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature (2017) 0.75
miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood (2017) 0.75
NLRC3 regulates cellular proliferation and apoptosis to attenuate the development of colorectal cancer. Cell Cycle (2017) 0.75
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Curr Treat Options Oncol (2017) 0.75
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol (2017) 0.75
Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma. Mol Cancer Ther (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell (1992) 17.50
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A (1995) 5.06
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics (2008) 3.62
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Cellular origin of human B-cell lymphomas. N Engl J Med (1999) 2.91
Analysis of the B-cell progenitor compartment at the level of single cells. Curr Biol (1994) 2.15
Burkitt lymphoma in the mouse. J Exp Med (2000) 1.96
Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity (2006) 1.94
Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell (2010) 1.85
Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med (2010) 1.84
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res (2005) 1.83
The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol (2008) 1.79
Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc Natl Acad Sci U S A (2006) 1.78
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A (2008) 1.69
Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia (2008) 1.43
Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program (2011) 1.28
Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol (2010) 1.24
Requirement for cyclin D3 in germinal center formation and function. Cell Res (2010) 1.16
The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res (1992) 1.14
The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood (2009) 1.11
P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene (2004) 1.09
Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol (2006) 1.07
High-dimensional data analysis: selection of variables, data compression and graphics--application to gene expression. Biom J (2009) 1.02
Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A (2011) 1.02
Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. Int J Cancer (2012) 0.92
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol (2001) 0.91
PTEN deletion and concomitant c-Myc activation do not lead to tumor formation in pancreatic beta cells. J Biol Chem (2008) 0.89
Myc oncogene activation in B and T lymphoid tumours. Proc R Soc Lond B Biol Sci (1985) 0.86
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
MicroRNA control in the immune system: basic principles. Cell (2009) 7.16
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol (2003) 7.06
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med (2014) 6.80
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Aberrant T cell differentiation in the absence of Dicer. J Exp Med (2005) 6.58
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
IgH class switching and translocations use a robust non-classical end-joining pathway. Nature (2007) 6.05
Microbial exposure during early life has persistent effects on natural killer T cell function. Science (2012) 5.90
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 5.70
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53
Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity (2008) 5.03
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol (2006) 4.49
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell (2004) 4.31
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Vagaries of conditional gene targeting. Nat Immunol (2007) 3.51
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
Regulation of microRNA expression and abundance during lymphopoiesis. Immunity (2010) 3.29
TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol (2010) 3.26
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2011) 3.21
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 3.21
Double-hit B-cell lymphomas. Blood (2010) 3.19
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 3.17
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood (2005) 3.14
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A (2011) 3.07
Yin Yang 1 is a critical regulator of B-cell development. Genes Dev (2007) 3.06
B cell receptor signal strength determines B cell fate. Nat Immunol (2004) 3.06
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain (2009) 3.04
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci U S A (2002) 3.01
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2012) 3.00
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med (2009) 2.80
Rapid generation of inducible mouse mutants. Nucleic Acids Res (2003) 2.77
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res (2007) 2.71
Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.66
Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet (2002) 2.65
miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood (2008) 2.58
T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med (2004) 2.58
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
FCGR3 variants and expression of human neutrophil antigen-1a, -1b, and -1c in the populations of northern Germany and Uganda. Transfusion (2002) 2.52
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol (2004) 2.51
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Hair loss and defective T- and B-cell function in mice lacking ORAI1. Mol Cell Biol (2008) 2.50
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
High-resolution description of antibody heavy-chain repertoires in humans. PLoS One (2011) 2.36
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol (2012) 2.35
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med (2011) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity (2007) 2.28
FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn (2006) 2.28
Mechanisms promoting translocations in editing and switching peripheral B cells. Nature (2009) 2.27